- Stocks
- Pharma & Healthcare
- Zenotech Labs
Zenotech Labs share price
NSE: ZENOTECHPharma & HealthcareDrug Manufacturers - Specialty & Generic
Zenotech Labs at a glance
With a market capitalisation of ₹270 Cr, it ranks 2111th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −13.0% in FY10. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹93 Cr (−13.9% year on year) and net profit ₹8 Cr (+343.2%), on a consolidated basis. Promoters held 68.84% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹270 CrRank 2111 on NSE
- Price to book
- 4.03×FY10
- EPS (TTM)
- ₹1.38to Q1 FY27
- ROE
- −13.0%FY10
- ROCE
- −11.7%FY10
- Debt to equity
- 0.11FY10
- Net profit margin
- −189.8%FY10
- Book value / share
- ₹28.02FY10
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Zenotech Labs quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹58 Cr | ₹75 Cr | ₹159 Cr | ₹108 Cr | ₹74 Cr | ₹80 Cr | ₹177 Cr | ₹93 Cr |
| Revenue YoY | −12.4% | +10.3% | +36.2% | +34.9% | +27.6% | +6.6% | +11.4% | −13.9% |
| Net profit | −₹4 Cr | −₹4 Cr | ₹17 Cr | ₹2 Cr | −₹6 Cr | −₹3 Cr | ₹45 Cr | ₹8 Cr |
| Net profit YoY | — | — | −90.0% | −47.8% | — | — | +169.2% | +343.2% |
| Net margin | −6.9% | −5.0% | 10.6% | 1.8% | −8.3% | −3.3% | 25.7% | 9.0% |
| EPS | −₹0.12 | −₹0.12 | ₹0.52 | ₹0.06 | −₹0.19 | −₹0.08 | ₹1.39 | ₹0.26 |
Zenotech Labs financials
| Item | FY06 | FY07 | FY08 | FY09 | FY10 |
|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹13 Cr | ₹8 Cr | ₹6 Cr | ₹7 Cr |
| Operating profit | −₹3 Cr | −₹1 Cr | −₹14 Cr | −₹18 Cr | −₹13 Cr |
| Net profit | −₹4 Cr | ₹2 Cr | −₹16 Cr | −₹18 Cr | −₹13 Cr |
| EPS (₹) | −₹3.00 | ₹1.00 | −₹5.00 | −₹5.00 | −₹4.00 |
| Cash from operations | −₹16 Cr | −₹7 Cr | −₹3 Cr | −₹16 Cr | −₹10 Cr |
| Total debt | ₹27 Cr | ₹30 Cr | ₹14 Cr | ₹12 Cr | ₹10 Cr |
| Shareholders' equity | ₹21 Cr | ₹54 Cr | ₹126 Cr | ₹109 Cr | ₹96 Cr |
Zenotech Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 30.17% | 30.17% | 30.17% | 30.17% | 30.17% | 30.17% |
Zenotech Labs vs peers
The listed Pharma & Healthcare companies nearest to Zenotech Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMBALALSAAmbalal Sarabhai Enterprises | ₹36.20 | −1.09% | — | ₹277 Cr | 15.6 | — |
| ESPIREEspire Hospital | — | — | — | ₹274 Cr | — | — |
| ZENOTECHZenotech Labs | — | — | — | ₹270 Cr | — | — |
| EVERESTOEverest Organic | — | — | — | ₹262 Cr | — | — |
| GENNEXGennex Labs | — | — | — | ₹254 Cr | — | — |
| KERALAYURKerala Ayur | — | — | — | ₹254 Cr | — | — |
| NATHBIOGENNath Bio-Genes (India) | ₹132.60 | +0.76% | −23.0% | ₹252 Cr | 6.3 | — |
Ask anything about Zenotech Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against ZENOTECH's own history. Try: “Why has ZENOTECH moved over the last three months?” · “Backtest a 50-day moving-average crossover on ZENOTECH over five years” · “Compare ZENOTECH with AMBALALSA on margins and valuation”
Frequently asked questions about Zenotech Labs
What is the market cap of Zenotech Labs?
Zenotech Labs' market capitalisation is ₹270 Cr (₹270 Cr) at the 22 Oct 2026 close, ranking 2111th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Zenotech Labs?
Return on equity was −13.0% in FY10 and return on capital employed was −11.7% in FY10 (consolidated figures).
Is Zenotech Labs a debt-free company?
No. Zenotech Labs' debt-to-equity ratio was 0.11 in FY10, with total debt of ₹10 Cr.
What were Zenotech Labs' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Zenotech Labs reported revenue of ₹93 Cr, −13.9% year on year, and net profit of ₹8 Cr, +343.2% year on year.
What is the shareholding pattern of Zenotech Labs?
As of 30 Jun 2026: promoters 68.84%, domestic institutions 0.01%, non-institutions 30.17%.
Who are Zenotech Labs' competitors?
The listed Pharma & Healthcare companies closest to Zenotech Labs by market cap are Ambalal Sarabhai Enterprises, Espire Hospital, Everest Organic, Gennex Labs, Kerala Ayur and Nath Bio-Genes (India).
Is Zenotech Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Zenotech Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZENOTECH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with Z · all NSE stocks · this page as text